A 68-year-old man presents with fatigue and pancytopenia. Bone marrow biopsy shows 35% blasts. Cytogenetics reveal the karyotype marked **B** in the diagram: monosomy 7, deletion 5q, and trisomy 8. Molecular testing shows TP53 mutation. According to the 2022 ELN guidelines, what is the risk stratification and most appropriate initial management for this patient?
A. Adverse risk; induction chemotherapy (7+3) followed by allogeneic HSCT in first remission
B. Very adverse risk; palliative care only given TP53 mutation
C. Favorable risk; LDAC alone with supportive care
D. Intermediate risk; venetoclax monotherapy with close monitoring
Explanation
Why "Adverse risk; induction chemotherapy (7+3) followed by allogeneic HSCT in first remission" is right
The karyotype marked B — with ≥3 unrelated chromosomal abnormalities (monosomy 7, del(5q), trisomy 8) in the absence of WHO-recognized recurrent translocations — defines complex karyotype AML. Per the 2022 ELN guidelines, complex karyotype AML is classified as ADVERSE RISK, regardless of TP53 status. Although TP53 mutation (present in ~70% of complex karyotype cases) further worsens prognosis, the patient is 68 years old and fit enough for intensive therapy. The standard of care for fit patients <75 years with adverse-risk AML is induction with 7+3 (cytarabine 100–200 mg/m²/day × 7 days + daunorubicin 60–90 mg/m²/day × 3 days) followed by allogeneic HSCT in first complete remission, which is the only potentially curative approach. [Döhner Blood 2022 ELN guidelines; WHO 5e 2022]
Why each distractor is wrong
Intermediate risk; venetoclax monotherapy with close monitoring: Complex karyotype AML is ADVERSE risk, not intermediate. Venetoclax monotherapy is reserved for unfit/elderly patients (typically ≥75 years) who cannot tolerate intensive chemotherapy; this 68-year-old is a candidate for induction.
Favorable risk; LDAC alone with supportive care: Complex karyotype AML is ADVERSE risk, not favorable. LDAC (low-dose cytarabine) is used in unfit elderly patients, not as primary therapy in fit patients. Favorable risk includes t(8;21), inv(16), and t(15;17) — none of which are present here.
Very adverse risk; palliative care only given TP53 mutation: While TP53 mutation does carry worse prognosis within the complex karyotype cohort, it does not automatically mandate palliative care in a fit 68-year-old. Intensive induction followed by HSCT remains the standard, with 5-year post-HSCT survival of 20–35%, which is substantially better than untreated disease.
High-YieldNEET PG
Complex karyotype = ≥3 unrelated abnormalities (no recurrent translocations) = ADVERSE ELN risk = induction + allo-HSCT in first CR for fit patients; TP53 mutation worsens prognosis but does not change initial management strategy.
[Döhner Blood 2022 ELN guidelines; WHO 5e 2022]
Practice similar questions
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.
